Study of the anticoagulant effect of nafamostat mesylate in hemodialysis
Objective:To investigate the anticoagulant effect of nafamostat mesylate in hemodialysis.Methods:A total of 81 patients who underwent hemodialysis treatment in our hospital between September 2022 and May 2024 were selected and ran-domly assigned to a control group and an observation group.In the control group(n=41),heparin sodium was chosen as the anti-coagulant,while in the observation group(n=40),nafamostat mesylate was selected as the anticoagulant.The anticoagulant ef-fectiveness rate,coagulation parameters,and compression hemostasis time at the arterial puncture site were compared between the two groups.Results:The observation group exhibited a higher anticoagulant effectiveness rate compared to the control group,but the difference was not statistically significant(P＞0.05).There were no statistically signif-icant differences in prothrombin time(PT)and fibrinogen(FIB)levels between the two groups(P＞0.05).However,the observation group had significantly lower thrombin time(TT)and activated partial thromboplastin time(APTT)levels,as well as a shorter compression hemostasis time at the arterial puncture site,compared to the control group,with statistically significant differences(P＜0.05).Conclusion:In patients undergoing hemodi-alysis treatment,the use of nafamostat mesylate demonstrates good anticoagulant efficacy with minimal impact on coagulation param-eters and can effectively shorten the compression hemostasis time at the arterial puncture site,making it worthy of clinical promotion and application.
万方数据
维普
